Skip to main content
Premium Trial:

Request an Annual Quote

Former Gen-Probe Execs Partner with Private Equity Firm to Launch Maravai Life Sciences

NEW YORK (GenomeWeb News) – Private equity firm GTCR today announced a partnership with former Gen-Probe executives Carl Hull and Eric Tardif to form Maravai Life Sciences.

Based in San Diego, Maravai will acquire diagnostics and life science companies and products "as part of a strategy to build a market-leading healthcare business," GTCR said, adding it is investing up to $300 million into the partnership.

Maravai's strategy is to acquire companies and accelerate their growth by investing cash into the operations, acquiring complementary businesses or product lines, and leveraging Hull and Tardif's expertise in the diagnostics and life sciences arenas.

Hull was the CEO of Gen-Probe and shepherded the firm as it was being acquired for $3.8 billion by Hologic in 2012. He also has held executive positions at Applied Biosystems, now part of Thermo Fisher Scientific, Ventana Medical Systems, and Abbott Laboratories.

Tardif was a senior VP at Gen-Probe and was responsible for creating a corporate strategy, and evaluating and executing mergers and acquisitions.

Maravai said on its website that it is interested in firms focused mainly in the in vitro diagnostics, diagnostic laboratory services, and life sciences tools markets. The companies should have leadership positions in their principal operating segments "driven by either proprietary products or services," and have "clear" revenue growth opportunities with annual operating earnings of at least $15 million, generally.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.